NEW YORK, Nov. 4, 2013 /PRNewswire/ -- Wolf Popper LLP has filed a class action lawsuit against Amarin Corp. plc ("Amarin") (NASD: AMRN), and Joseph S. Zakrzewski (Amarin's CEO), in the United States District Court for the District of New Jersey, on behalf of all persons who purchased shares of Amarin common stock on the open market, or pursuant to Registration Statements filed with the SEC, during the period July 9, 2009 through October 15, 2013, and who were damaged thereby. This action alleges claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The Complaint charges that defendants misrepresented the prospects for Food and Drug Administration ("FDA") approval of Amarin's Vascepa drug for the ANCHOR indication and failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk. Persons who purchased Amarin common stock during the Class Period are urged to contact Wolf Popper to discuss their rights. If you are a member of the Class, you may move the Court no later than January 3, 2014, and request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. To be appointed lead plaintiff, the Court must decide that your claim is typical of the claims of other class members, and that you will adequately represent the class. Wolf Popper LLP has extensive experience representing shareholders in securities class actions and has successfully recovered billions of dollars for defrauded investors. The reputation and expertise of the firm in shareholder and other class action litigation has been repeatedly recognized by the courts, which have appointed the firm to major positions in complex multi-district and consolidated litigations.